Neuroblastoma pp 289-291 | Cite as

Perspectives and Future Directions

  • Nai-Kong V. Cheung
  • Susan L. Cohn
Part of the Pediatric Oncology book series (PEDIATRICO)


Clin Oncol Minimal Residual Disease Pediatric Oncology Group Study Chemotherapy Dose Intensity Favorable Prognostic Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 3:203–216CrossRefPubMedGoogle Scholar
  2. Cheung NK, Heller G (1991) Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050–1058PubMedGoogle Scholar
  3. George RE, London WB, Maris JM, Cohn SL, Diller L, Brodeur GM, Castleberry RP, Look AT. Hyperdiploidy plus Non-amplified MYCN Confers a Favorable Prognostic Group in Children 12 to 18 Month of Age with Disseminated Neuroblastoma: A Pediatric Oncology Group Study. J Clin Oncol (in press)Google Scholar
  4. Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M, Adams R, Grier HE, Gorlin JB, Shamberger R, Marcus K, Neuberg D, Weinstein HJ, Diller L (2000) Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. J Clin Oncol 18:2567–2575PubMedGoogle Scholar
  5. Kletzel M, Katzenstein HM, Haut PR, Yu AL, Morgan E, Reynolds M, Geissler G, Marymount MH, Liu D, Kalapurakal JA, Shore RM, Bardo DM, Schmoldt J, Rademaker AW, Cohn SL (2002) Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol 20:2284–2292CrossRefPubMedGoogle Scholar
  6. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing RB, Reynolds CP (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cisretinoic acid. N Engl J Med 341:1165–1173CrossRefPubMedGoogle Scholar
  7. Schmidt ML, Lal A, Seeger RC, Maris JM, Shimada H, O'Leary M, Gerbing RB, Matthay KK. Favorable prognosis for patients ages 12–18 month with stage 4 MYCN-nonamplified neuroblastoma. J Clin Oncol (in press)Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2005

Authors and Affiliations

  • Nai-Kong V. Cheung
  • Susan L. Cohn

There are no affiliations available

Personalised recommendations